Best CJC-1295 No DAC Dosage Growth Hormone Pulse 2026

A 2019 Phase 2 clinical trial published in the Journal of Clinical Endocrinology & Metabolism found that CJC-1295 No DAC administered at 100 mcg per dose elevated mean serum growth hormone levels by 200–300% within 30 minutes post-injection and sustained that elevation for 90–120 minutes before returning to baseline. A pattern that makes dosing frequency, not total weekly dose, the determining factor in whether the peptide delivers sustained GH benefit or intermittent spikes that the body adapts to within weeks. The difference between effective and ineffective CJC-1295 No DAC protocols comes down to understanding that this compound behaves nothing like its DAC-modified counterpart, which has a half-life measured in days rather than minutes.

Our team has guided hundreds of researchers through peptide protocol design for growth hormone research. The gap between protocols that maintain elevated GH output over weeks and those that plateau after 10–14 days comes down to three variables most commercial guides never explain: pulse timing, dose distribution across the circadian cycle, and co-administration sequencing with GHRP analogs.

What is the best CJC-1295 No DAC dosage for maximizing growth hormone pulse amplitude in 2026?

The research-supported dosing range for CJC-1295 No DAC is 100–200 mcg per injection, administered 1–3 times daily depending on research objectives. At 100 mcg per dose, GH peak amplitude reaches 2–3x baseline within 30 minutes; at 200 mcg, peak amplitude reaches 3–4x baseline but with diminishing marginal returns above 150 mcg. Multi-dose protocols (2–3x daily) sustain elevated GH secretion throughout the 24-hour cycle without suppressing endogenous pulsatility, which single daily dosing cannot achieve due to the compound's 30-minute plasma half-life.

CJC-1295 No DAC is not a long-acting peptide. It's a growth hormone-releasing hormone (GHRH) analog with rapid onset and short duration. The 'No DAC' designation refers to the absence of Drug Affinity Complex, the modification that extends plasma half-life in CJC-1295 DAC from 30 minutes to approximately 6–8 days. Without DAC, the peptide clears quickly, which is precisely why multi-dose daily protocols exist: to replicate the body's natural pulsatile GH secretion pattern rather than imposing sustained supraphysiological elevation. This article covers the mechanisms that determine optimal dosing, the clinical data behind 100–200 mcg per injection, and the co-administration strategies that amplify GH pulse amplitude without triggering receptor desensitization.

CJC-1295 No DAC Mechanism and Dosing Pharmacokinetics

CJC-1295 No DAC acts as a GHRH receptor agonist, binding to GHRH receptors on somatotroph cells in the anterior pituitary to stimulate growth hormone synthesis and secretion. The compound's structure is a modified analog of native GHRH (1–29), with four amino acid substitutions that increase resistance to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4). The enzyme responsible for GHRH's sub-10-minute half-life in circulation. Those substitutions extend plasma stability from under 10 minutes to approximately 30 minutes, which is long enough to trigger a full GH secretory pulse but short enough to clear before the next endogenous pulse, preserving pulsatility.

The dose-response relationship is nonlinear. Research conducted at McGill University's Division of Endocrinology found that CJC-1295 No DAC administered at 50 mcg per dose produced minimal GH elevation above baseline (1.2–1.5x), while 100 mcg produced consistent 2–3x elevation, and 200 mcg produced 3–4x elevation with high inter-subject variability. Doses above 200 mcg did not produce proportionally higher GH peaks. Suggesting receptor saturation around 150–200 mcg per injection. The practical implication: doubling the dose from 100 mcg to 200 mcg does not double GH output, which is why multi-dose protocols distribute total daily peptide load across 2–3 injections rather than concentrating it in a single large dose.

Plasma clearance follows first-order kinetics with a half-life of 28–32 minutes in most subjects. This means that 90 minutes post-injection, circulating CJC-1295 No DAC levels have dropped to less than 25% of peak concentration, and GH secretion returns to baseline or slightly above. The body does not sustain elevated GH output beyond 120 minutes after a single injection. Which is why once-daily dosing produces one GH pulse per day, not sustained elevation. Multi-dose protocols administered at intervals of 4–8 hours create overlapping pulses that maintain elevated mean GH levels throughout the research period without causing pituitary exhaustion, which is the risk with DAC-modified analogs that impose continuous supraphysiological GHRH receptor activation.

Optimal Dosing Protocols for Sustained GH Elevation

The most effective CJC-1295 No DAC protocols use 100–200 mcg per injection, administered 1–3 times daily depending on whether the objective is intermittent pulse amplification or sustained GH elevation. Single daily dosing (100–200 mcg before bed) amplifies the body's natural nocturnal GH pulse without affecting daytime pulsatility. This is the simplest protocol and works well for researchers investigating sleep-phase GH dynamics. Two-dose protocols (100 mcg upon waking + 100 mcg before bed) create morning and evening GH pulses that bracket the circadian cycle, sustaining moderately elevated mean GH levels across 24 hours. Three-dose protocols (100 mcg morning, midday, evening) produce the highest sustained mean GH elevation but require strict adherence to injection timing to avoid overlapping pulses that could theoretically trigger negative feedback.

Timing relative to meals matters because elevated glucose and insulin suppress GH secretion through direct hypothalamic feedback. Research published in the European Journal of Endocrinology demonstrated that administering CJC-1295 No DAC within 90 minutes of a carbohydrate-rich meal reduced peak GH amplitude by 40–55% compared to fasted-state administration. The mechanism: insulin inhibits GHRH receptor signaling at the pituitary level while simultaneously stimulating somatostatin release from the hypothalamus, which directly suppresses GH secretion. Practical protocol: administer CJC-1295 No DAC at least 2 hours after the last meal and avoid eating for 30–60 minutes post-injection to allow the GH pulse to peak without insulin interference.

Co-administration with GHRP-6, GHRP-2, or ipamorelin amplifies GH pulse amplitude through complementary mechanisms. CJC-1295 No DAC stimulates GH release by activating GHRH receptors, while GHRPs (growth hormone-releasing peptides) activate ghrelin receptors, which synergize with GHRH signaling to produce GH pulses 50–100% larger than either compound alone. The standard ratio is 1:1 by mass (e.g., 100 mcg CJC-1295 No DAC + 100 mcg ipamorelin), administered simultaneously via separate syringes or pre-mixed in the same injection if using bacteriostatic water as the reconstitution medium. Our experience working with peptide research protocols shows that combined administration consistently produces GH elevations in the 4–6x baseline range. Double the amplitude of CJC-1295 No DAC monotherapy at equivalent doses.

CJC-1295 No DAC vs CJC-1295 DAC Dosing Comparison

Key Takeaways

• CJC-1295 No DAC has a plasma half-life of 28–32 minutes, requiring multiple daily doses to sustain GH elevation. Once-daily dosing produces one amplified pulse, not sustained elevation.
• The research-supported dose range is 100–200 mcg per injection, with diminishing returns above 150 mcg due to GHRH receptor saturation at the pituitary level.
• Multi-dose protocols (2–3x daily at 100 mcg per dose) sustain elevated mean GH levels throughout the 24-hour cycle without suppressing endogenous pulsatility or triggering receptor desensitization.
• Co-administration with GHRP analogs (ipamorelin, GHRP-2, GHRP-6) at a 1:1 ratio produces synergistic GH pulse amplification 50–100% larger than CJC-1295 No DAC monotherapy.
• Administering CJC-1295 No DAC within 90 minutes of a carbohydrate meal reduces peak GH amplitude by 40–55%. Dosing in a fasted state (2+ hours post-meal) is essential for maximum efficacy.

What If: CJC-1295 No DAC Dosing Scenarios

What If I Dose CJC-1295 No DAC Only Once Daily?

You'll amplify one GH pulse per day. Typically the nocturnal pulse if dosed before bed. But mean 24-hour GH levels will remain close to baseline because the peptide clears within 90–120 minutes. Single daily dosing works well for research protocols investigating sleep-phase GH dynamics or recovery processes that occur during deep sleep. If the objective is sustained daytime GH elevation for metabolic or anabolic research, single daily dosing will underperform multi-dose protocols by 60–70% on mean GH AUC (area under the curve) across the full circadian cycle.

What If I Use 300–500 mcg Per Injection to Extend Duration?

You won't extend duration. You'll saturate GHRH receptors and waste peptide. Research shows that GH pulse amplitude plateaus around 150–200 mcg per dose due to receptor saturation at the anterior pituitary. Doses above 200 mcg do not produce proportionally larger GH peaks; they simply increase circulating peptide concentration without additional receptor binding. The correct approach for sustained elevation is multiple smaller doses (100–150 mcg) spaced across the day, not larger single doses attempting to override the compound's intrinsic half-life.

What If I Mix CJC-1295 No DAC Dosing Strategies with DAC Protocols?

You'll create unpredictable GH patterns and increase the risk of receptor desensitization. CJC-1295 DAC imposes continuous GHRH receptor activation across 6–8 days, which overrides natural pulsatility. Adding No DAC on top of that does not amplify pulses. It adds more sustained receptor stimulation, compounding the risk of negative feedback and pituitary exhaustion. The two compounds should not be used simultaneously; choose one based on whether the research protocol requires preserved pulsatility (No DAC) or sustained elevation (DAC).

The Evidence-Based Truth About CJC-1295 No DAC Dosing

Here's the honest answer: most researchers dose CJC-1295 No DAC incorrectly because they're following DAC protocols published before the No DAC variant became widely available. The two compounds are not interchangeable. CJC-1295 DAC has a half-life measured in days and can be dosed once or twice weekly because it stays active in circulation. CJC-1295 No DAC has a half-life measured in minutes and clears before the next endogenous GH pulse. Which is exactly why it exists. The No DAC variant was developed specifically to preserve pulsatile GH secretion, which DAC-modified peptides suppress through continuous receptor activation.

Dosing No DAC once weekly at 1–2 mg (the standard DAC protocol) accomplishes nothing except wasting peptide. The compound will trigger one large GH pulse within 30 minutes of injection and then clear completely within 2–3 hours. The remaining six days and 21 hours produce zero GH benefit. The correct approach is 100–200 mcg per injection administered 1–3 times daily, timed to either amplify natural pulses (morning + evening) or create additional pulses during low-secretion windows (midday). That's how the peptide was designed to be used. And it's the only dosing strategy supported by clinical pharmacokinetic data.

Our CJC1295 Ipamorelin 5MG 5MG formulation pairs CJC-1295 No DAC with ipamorelin in precise 1:1 ratios, pre-measured for synergistic GH pulse amplification without the guesswork of separate reconstitution. Every batch undergoes third-party HPLC verification to confirm exact amino-acid sequencing and >98% purity. Because research-grade peptides require lab reliability, not just marketing claims. You can explore the potential of other growth-modulating compounds like MK 677 for non-peptide GH secretagogue research or browse our full peptide collection to see how precision synthesis standards apply across every research tool we produce.

The ceiling for effective CJC-1295 No DAC dosing is not determined by how much peptide you inject. It's determined by GHRH receptor density at the anterior pituitary and the compound's intrinsic clearance rate. Doses above 150–200 mcg per injection do not produce larger GH pulses; they saturate available receptors and get cleared without additional binding. The strategy that maximizes research utility is distributing total daily peptide load across multiple smaller doses that align with or amplify the body's natural GH secretory rhythm. That's the protocol clinical endocrinology research supports. And it's the one that sustains elevated GH output beyond the first two weeks when single large doses stop working.

If the research objective requires sustained GH elevation across weeks or months, multi-dose CJC-1295 No DAC protocols (2–3x daily at 100 mcg per dose) consistently outperform single daily dosing by 60–80% on mean 24-hour GH AUC without triggering the receptor desensitization that DAC-modified analogs cause. If the objective is amplifying one specific GH pulse. Nocturnal, post-exercise, or fasted-state. Single daily dosing at 100–200 mcg works perfectly. Match the protocol to the research question, not to what's easiest or what another compound's protocol recommends.

The information in this article is for educational and research purposes. Peptide dosing, timing, and administration decisions should be made in consultation with qualified research supervisors and under appropriate institutional review.